PSX Company Profiles
What listed companies do, how they make money, key financials and Shariah status, researched by the PSX Investors Zone team.
2 companies
Pharmaceuticals
BF Biosciences Limited
BF Biosciences Limited (BFBIO) is a Pakistan Stock Exchange-listed pharmaceutical company engaged in developing, manufacturing, marketing and distributing pharmaceutical products. It is an 80:20 joint venture between Ferozsons Laboratories Limited and Argentina's Bagó Group. In FY2026, the company reported revenue of Rs.9.46 billion and profit after tax of Rs.632.13 million, reflecting strong year-on-year growth. BFBIO was classified as Shariah-compliant in the PSX screening effective May 29, 2026. Investors should review its latest financial reports, expansion spending, regulatory developments and current Shariah status before making investment decisions.
Pharmaceuticals
Ferozsons Laboratories Limited
Ferozsons Laboratories Limited (PSX: FEROZ) is a Pakistani pharmaceutical company incorporated in 1954 that commenced commercial operations in 1956. Its core business includes importing, manufacturing and selling pharmaceutical products and medical devices. The company also has interests in BF Biosciences Limited, a pharmaceutical business, and Farmacia, a medicine retail and distribution venture. For FY2026, Ferozsons reported standalone revenue of approximately Rs. 15.76 billion, profit after tax of Rs. 650.90 million and EPS of Rs. 14.97. On a consolidated basis, revenue reached Rs. 23.96 billion and profit after tax was approximately Rs. 1.23 billion, with consolidated EPS of Rs. 22.51. The board recommended a final cash dividend of Rs. 5.50 per share for FY2026, subject to shareholder approval at the AGM scheduled for October 28, 2026. Ferozsons appeared as Shariah-compliant in the PSX-KMI All Share Islamic Index screening information effective June 5, 2026, based on December 2025 data. Investors should verify the latest screening status. **Important PSX Risk Warning:** The official PSX company page displays an alert concerning continuous violation of specified listing-regulation clauses and potential trading suspension or delisting. Investors should review the latest official notice and company disclosures before making investment decisions.